RA Capital Management 13F holdings, Q2 2017
Holdings as of June 30, 2017 · filings on SEC EDGAR · latest filing →
RA Capital Management disclosed 22 US equity positions worth $871.4m in its Q2 2017 13F filing. The largest position was ASND at 17.8% of the reported book, followed by WVE and AVEXIS INC. Against the Q1 2017 filing, it opened 7 new positions, added to 6 and reduced 3 among the top 22 holdings.
What did RA Capital Management own in Q2 2017? Top 22 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q1 2017 |
|---|---|---|---|---|---|---|---|
| 1 | ASND ASCENDIS PHARMA A S | Healthcare | 17.8% | $154.9m | 5,580,690 | 3% | added |
| 2 | WVE WAVE LIFE SCIENCES LTD | Healthcare | 15.1% | $131.8m | 7,088,651 | 0% | held |
| 3 | AVEXIS INC | 12.4% | $107.6m | 1,310,046 | -19% | reduced | |
| 4 | ACHILLION PHARMACEUTICALS INC | 7.2% | $62.6m | 13,633,220 | 0% | held | |
| 5 | BIOHAVEN PHARMACTL HLDG CO LTD | 7.0% | $61.2m | 2,448,350 | – | new | |
| 6 | G1 THERAPEUTICS INC | 5.4% | $46.8m | 2,684,244 | – | new | |
| 7 | IGNYTA INC | 4.8% | $41.6m | 4,016,990 | 292% | added | |
| 8 | ESPERION THERAPEUTICS INC | 3.9% | $33.9m | 731,531 | 4% | added | |
| 9 | MYOVANT SCIENCES LTD | 3.8% | $32.8m | 2,807,550 | 20% | added | |
| 10 | BCRX BIOCRYST PHARMACEUTICALS | Healthcare | 3.3% | $28.7m | 5,162,242 | 48% | added |
| 11 | RA PHARMACEUTICALS INC | 2.9% | $25.3m | 1,351,808 | 0% | held | |
| 12 | RADIUS HEALTH INC | 2.6% | $22.5m | 497,157 | – | new | |
| 13 | ZOGENIX INC | 2.5% | $21.4m | 1,474,688 | -40% | reduced | |
| 14 | AQUINOX PHARMACEUTICALS INC | 2.3% | $19.6m | 1,396,071 | -36% | reduced | |
| 15 | AVEO PHARMACEUTICALS INC | 2.1% | $18.7m | 8,435,584 | – | new | |
| 16 | ACORDA THERAPEUTICS INC | 2.0% | $17.7m | 900,259 | 84% | added | |
| 17 | AKBA AKEBIA THERAPEUTICS INC | Healthcare | 1.4% | $12.0m | 836,337 | – | new |
| 18 | SGMOQ SANGAMO THERAPEUTICS INC | Healthcare | 1.3% | $11.0m | 1,250,000 | – | new |
| 19 | DICERNA PHARMACEUTICALS INC | 0.9% | $7.7m | 2,428,571 | 0% | held | |
| 20 | TGTX TG THERAPEUTICS INC | Healthcare | 0.8% | $7.0m | 700,000 | 0% | held |
| 21 | 4XC1 KALVISTA PHARMACEUTICALS INC | 0.5% | $4.3m | 591,070 | 0% | held | |
| 22 | PROTEON THERAPEUTICS INC | 0.2% | $2.0m | 1,337,462 | – | new |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.